Joe Todisco, CEO of CorMedix, a biopharmaceutical company focused on developing and commercializing therapeutic products that prevent infection and other life-threatening conditions, discusses the dangers of hospital and other related infections, as well as the urgency behind the global expansion of antimicrobial resistance, which is on the rise. He also talks about the company’s investigational catheter lock solution, DefenCath™, to reduce the risk of catheter-related bloodstream infections (CBRSIs) from central venous catheters (CVCs), which can dramatically increase hospital costs and length of stay. An NDA has been submitted to the FDA.
Mr. Joe Todisco is Chief Executive Officer of CorMedix and a member of the Board of Directors. Prior to joining CorMedix, he spent eleven years in various roles at Amneal Pharmaceuticals, most recently as Chief Commercial Officer of Amneal Specialty, as well as Senior Vice President Corporate Development & International Operations. He was also co-founder and formerly chief executive of Gemini Laboratories LLC, a specialty pharmaceutical company that was subsequently acquired by Amneal. Prior to joining Amneal, Joe spent more than five years leading Ranbaxy Pharmaceutical’s North American Commercial Strategy and Business Development, and prior to Ranbaxy, held various leadership roles with Par Pharmaceuticals. Joe holds a bachelor’s degree in Economics from Georgetown University and an M.B.A. from Fordham Graduate School of Business.